According to Nova one advisor, the global Immunohistochemistry market size was estimated at USD 2.75 billion in 2022 and is projected to hit around USD 4.19 billion by 2030, growing at a CAGR of 8.29% during the forecast period 2022 to 2030.
According to Nova one advisor, the global Immunohistochemistry market size was estimated at USD 2.75 billion in 2022 and is projected to hit around USD 4.19 billion by 2030, growing at a CAGR of 8.29% during the forecast period 2022 to 2030.
Get the Free Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/7594
Key Takeaways:
- The antibodies product segment led the market in 2021 owing to the high use of antibodies for immunohistochemistry assays carried out for disease diagnosis and drug testing workflows
- The diagnostics application segment led the market in 2021 owing to the widespread application of IHC tests in diagnostic settings
- The drug testing segment is expected to witness significant growth during the forecast period. This is due to increasing investment flow by pharmaceutical companies in R&D activities of novel drug discovery and development
- The hospitals and diagnostic laboratories end-use segment accounted for the largest revenue share in 2021. Research institutes are expected to register the fastest CAGR over the forecast period owing to the increasing adoption of IHC in research institutes for drug discovery activities
- North America emerged as the largest regional market in 2021 owing to the confluence of multiple factors, such as high cancer prevalence, presence of key players, and developed healthcare & biotechnological sectors
- The Asia Pacific is projected to grow at the fastest CAGRover the forecast period with China being the fastest-growing market. Increasing regulatory approvals and the launch of novel IHC solutions in China are accelerating the country’s market growth
- Key players are engaged in making focused attempts to reinforce their market position and gain a competitive advantage
Immediate Delivery Available | Buy this Premium Research Report@ https://www.novaoneadvisor.com/report/checkout/7594
Report Scope of the Immunohistochemistry Market
| Report Coverage | Details |
| Market Size | USD 4.19 Billion by 2030 |
| Growth Rate | CAGR of 8.29% from 2022 to 2030 |
| Largest Market | Asia Pacific |
| Fastest Growing Market | North America |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Product, application, end-use and Region, |
Increasing implementation of automation and machine learning in IHC, coupled with the introduction of technologically advanced Immunohistochemistry (IHC) solutions, is expected to significantly drive the market over the forecast period. Advancements in IHC protocols have boosted its demand to a significant level in disease diagnosis. In addition, the rise in product approvals and the launch of technologically advanced IHC systems for disease diagnosis are further propelling the market growth.
The high demand for accurate data has driven several technological advancements in IHC techniques, resulting in the delivery of precise and contextual data analyses. The emergence of advanced techniques, such as multiplex IHC, computational pathology, and next-generation IHC, is driving the global market. Immunohistochemistry protocols have gained popularity in clinical pathology, especially in the subspecialties of oncologic pathology, hematopathology, and neuropathology.
The technique has played a vital role in shaping cancer diagnostics. Thus, the growing prevalence of cancer is expected to increase the demand for IHC, thus contributing to market growth. Furthermore, the wide application scope of IHC in drug discovery and development activities is expected to boost revenue growth over the forecast period. Whole slide imaging and digital image analysis offer highly accurate and objective evaluations. Thus, image analysis can be used across different aspects of drug discovery including drug repositioning, target validation, patient stratification, biomarker expression studies, and drug efficacy & safety studies.
Acknowledging the profitable opportunities posed by the space, operating players in the industry continue to undertake strategic initiatives to strengthen their market presence. For instance, in June 2021, PathAI, in collaboration with AstraZeneca and Daiichi Sankyo Company Ltd., created machine learning-based models to enable automated quantification of HER2 IHC images in breast cancer samples. The global market will benefit from the growing geriatric population in developed and developing nations. As the global geriatric population increases, the prevalence of age-related illnesses is predicted to rise drastically.
Regional Insights
Based on regions, the global market has been further sub-categorized into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2021 and accounted for the largest share of more than 38.10% of the global revenue. Key factors contributing to the regional market growth include the presence of major market players, easy availability of IHC solutions, higher adoption of technologically advanced IHC instruments, and entry of newer IHC solutions.
For instance, in June 2021, PathAI, a U.S.-based developer of AI-powered technology for pathological applications, showcased a machine learning-based quality control tool, designed for HER2 testing in breast cancer, at the American society of clinical oncology virtual scientific program 2021. Asia Pacific is expected to witness the fastest CAGR during the forecast period. This is primarily due to the expansion of the geographic footprint of the global players in the Asian markets. Furthermore, a large patient pool in countries, such as India and China, provides a large number of clinical subjects to carry out IHC R&D assays, resulting in revenue growth.
Some of the prominent players in the Immunohistochemistry Market include:
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd.
- Merck KGaA
- Danaher Corporation
- Perkinelmer, Inc.
- Bio-Rad Laboratories, Inc.
- Cell Signaling Technology, Inc.
- Bio SB
- Agilent Technologies, Inc.
- Abcam plc.
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Immunohistochemistry market
- Product
- Antibodies
- Primary Antibodies
- Secondary Antibodies
- Equipment
- Slide Staining System
- Tissue Microarrays
- Tissue Processing Systems
- Slide Scanners
- Others
- Reagents
- Histological stains
- Blocking Sera and Reagents
- Chromogenic Substrates
- Fixation Reagents
- Stabilizers
- Organic Solvents
- Proteolytic Enzymes
- Diluents
- Kits
- IHC Kits for Human Tissue
- IHC Kits for Animal Tissue
- Antibodies
- Application
- Diagnostics
- Cancer
- Infectious Diseases
- Cardiovascular Diseases
- Autoimmune Diseases
- Diabetes Mellitus
- Nephrological Diseases
- Drug Testing
- Forensic applications
- Diagnostics
- End-use
- Hospitals & Diagnostic Laboratories
- Research Institutes
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7594
You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://www.visionresearchreports.com/
Blog: https://qyresearchmedical.com/